Therapeutic vaccines for allergic disease
Abstract Allergic diseases are highly prevalent worldwide and affect all age groups, contributing to a high personal and socioeconomic burden. Treatment with an “allergy vaccine” or allergen immunotherapy aims to provide long-lasting benefits by inducing unresponsiveness to the relevant antigen. The...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-05-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-017-0014-8 |
id |
doaj-94a5bc1adc39429493086bc6f92391b2 |
---|---|
record_format |
Article |
spelling |
doaj-94a5bc1adc39429493086bc6f92391b22020-12-07T23:56:37ZengNature Publishing Groupnpj Vaccines2059-01052017-05-012111010.1038/s41541-017-0014-8Therapeutic vaccines for allergic diseaseDanuta Gutowska-Owsiak0Graham S. Ogg1MRC Human Immunology Unit, NIHR Biomedical Research Centre, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of OxfordMRC Human Immunology Unit, NIHR Biomedical Research Centre, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of OxfordAbstract Allergic diseases are highly prevalent worldwide and affect all age groups, contributing to a high personal and socioeconomic burden. Treatment with an “allergy vaccine” or allergen immunotherapy aims to provide long-lasting benefits by inducing unresponsiveness to the relevant antigen. The consequences of the therapy are considered disease modifying and range from dampening of the immediate immune responses to the reduction of secondary tissue remodeling. Furthermore, allergen immunotherapy interventions have a potential to slow or cease the development of additional allergic manifestations with a long-term overall effect on morbidity and quality of life. Here, we review proposed mechanisms underlying the therapeutic effects of immunotherapy for allergic diseases. Further, we discuss both standard and novel approaches and possible future directions in the development of allergen immunotherapy.https://doi.org/10.1038/s41541-017-0014-8 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Danuta Gutowska-Owsiak Graham S. Ogg |
spellingShingle |
Danuta Gutowska-Owsiak Graham S. Ogg Therapeutic vaccines for allergic disease npj Vaccines |
author_facet |
Danuta Gutowska-Owsiak Graham S. Ogg |
author_sort |
Danuta Gutowska-Owsiak |
title |
Therapeutic vaccines for allergic disease |
title_short |
Therapeutic vaccines for allergic disease |
title_full |
Therapeutic vaccines for allergic disease |
title_fullStr |
Therapeutic vaccines for allergic disease |
title_full_unstemmed |
Therapeutic vaccines for allergic disease |
title_sort |
therapeutic vaccines for allergic disease |
publisher |
Nature Publishing Group |
series |
npj Vaccines |
issn |
2059-0105 |
publishDate |
2017-05-01 |
description |
Abstract Allergic diseases are highly prevalent worldwide and affect all age groups, contributing to a high personal and socioeconomic burden. Treatment with an “allergy vaccine” or allergen immunotherapy aims to provide long-lasting benefits by inducing unresponsiveness to the relevant antigen. The consequences of the therapy are considered disease modifying and range from dampening of the immediate immune responses to the reduction of secondary tissue remodeling. Furthermore, allergen immunotherapy interventions have a potential to slow or cease the development of additional allergic manifestations with a long-term overall effect on morbidity and quality of life. Here, we review proposed mechanisms underlying the therapeutic effects of immunotherapy for allergic diseases. Further, we discuss both standard and novel approaches and possible future directions in the development of allergen immunotherapy. |
url |
https://doi.org/10.1038/s41541-017-0014-8 |
work_keys_str_mv |
AT danutagutowskaowsiak therapeuticvaccinesforallergicdisease AT grahamsogg therapeuticvaccinesforallergicdisease |
_version_ |
1724397055037669376 |